MDXH (MDxHealth Inc.) יחס שווי שוק לשווי בספרים
This accompanying price chart helps assess the impact of implementing proprietary diagnostic systems and expanding insurance coverage, with the metric standing at -0.32. The MDxHealth SA (MDXH) business relies on the growing demand for molecular testing among US urological centers. The company is establishing an industry standard by integrating genetic screening into medical protocols to minimize redundant invasive procedures.
%20-%20%D7%99%D7%97%D7%A1%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_MDXH_-_MDxHealth-SA_-_Market-Cap-to-Net-Assets-Ratio "MDXH יחס שווי שוק לערך בספרים MDxHealth (04.07.2022 - 27.10.2026) | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור MDxHealth S.A. (MDXH)
Stable cash flow from prostate cancer molecular tests creates a resilient valuation foundation for MDxHealth SA (MDXH). This market-to-book ratio compares the current market valuation with net assets, demonstrating a premium or discount to the business's tangible capital. Analyzing this metric allows investors to determine the extent to which market expectations align with the company's material asset base.